Universal Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 28-06-2024
- Paid Up Capital ₹ 0.51 M
as on 28-06-2024
- Company Age 34 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.80 Cr
as on 28-06-2024
- Satisfied Charges ₹ 4.08 Cr
as on 28-06-2024
- Revenue 5.68%
(FY 2023)
- Profit 89.81%
(FY 2023)
- Ebitda 103.14%
(FY 2023)
- Net Worth -112.59%
(FY 2023)
- Total Assets 8.43%
(FY 2023)
About Universal Pharmaceuticals
The Corporate was formerly known as Universal Pharmaceuticals Ltd.. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 0.51 M.
The company currently has active open charges totaling ₹9.80 Cr. The company has closed loans amounting to ₹4.08 Cr, as per Ministry of Corporate Affairs (MCA) records.
Kalimuthu Babu and Shew Marda serve as directors at the Company.
- CIN/LLPIN
U24231TN1990PTC019449
- Company No.
019449
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Jul 1990
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Universal Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kalimuthu Babu  | Additional Director | Current | |
| Shew Marda | Director | 10-Aug-2006 | Current |
Financial Performance and Corporate Structure Insights of Universal Pharmaceuticals.
Universal Pharmaceuticals Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 5.68% increase. The company also saw a substantial improvement in profitability, with a 89.81% increase in profit. The company's net worth observed a substantial decline by a decrease of 112.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Universal Pharmaceuticals?
Unlock access to Universal Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 30 Dec 2017 | ₹0.55 M | Open |
Canara Bank Creation Date: 21 Sep 2006 | ₹4.29 Cr | Open |
Indian Bank Creation Date: 14 Aug 2004 | ₹2.73 Cr | Open |
How Many Employees Work at Universal Pharmaceuticals?
Universal Pharmaceuticals has a workforce of 50 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Universal Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Universal Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
